Impact of a higher radiation dose on local control and survival in breast-conserving therapy
of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.
Klsler, "Breast-conserving therapy
with partial or whole breast irradiation: tenyear results of the Budapest randomized trial," Radiotherapy & Oncology, vol.
Schnitt, "Outcome after breast-conserving therapy
for patients with stage I or II musinous, medullary, or tubular breast carcinoma," International Journal of Radiation Oncology Biology Physics, vol.
Angiosarcoma after breast-conserving therapy
: long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART).
They cover evolution of oncoplastic surgery, principles and considerations of oncoplastic breast conservation, immediate partial breast reconstruction, correction of the breast-conserving therapy
deformity: delayed partial breast reconstruction, and outcomes and future directions.
in breast cancer patients --a 12-year experience.
Quality of life over 5 years in women with breast cancer after breast-conserving therapy
versus mastectomy: a population-based study.
CHICAGO -- Women with clinical early-stage breast cancer and a positive sentinel lymph node who receive breast-conserving therapy
can safely skip an axillary lymph node dissection (ALND), and therefore avoid its associated morbidity, confirms long-term follow-up of the Z00 11 trial conducted by the American College of Surgeons Oncology Group and the Alliance for Clinical Trials in Oncology.
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy
in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
Mastectomy versus breast-conserving therapy
in the treatment of stage I and II carcinoma of the breast: A randomized trial at the National Cancer Institute.
(BCT), consisting of lumpectomy followed by radiotherapy, has become the standard form of treatment for invasive breast carcinomas up to 4-5cms and is increasingly being used for ductal carcinoma in situ (DCIS) and larger tumours.1-3 However, with BCT for large tumours, cosmetic outcome is often poor.4,5 The tumour size in relation to the breast size is one of the most important factors when attempting to obtain a cosmetically favourable result.